Top

In the spotlight.

From media giants to exclusive industry publications, Humacyte stays in the news.



June 12, 2018

Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment

March 9, 2018

Humacyte Closes $75 Million Series C Financing

October 2, 2017

Humacyte Awarded $3.4 Million Contract Award from The U.S. Department of Defense

September 29, 2017

Humacyte Receives $14.1 Million Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL®

September 27, 2017

Humacyte Receives Award from the Medical Technology Enterprise Consortium

September 7, 2017

Humacyte Completes Patient Enrollment for Phase III Clinical Trial of Human Acellular Vessel

June 14, 2017

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

April 25, 2017

Humacyte Founder Laura Niklason, M.D., Ph.D. Recognized on Fortune Magazine’s List of Leaders Transforming Health and Medicine

March 20, 2017

Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation for HUMACYL® in Vascular Access for Hemodialysis

December 29, 2016

Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial

August 8, 2016

California Institute for Regenerative Medicine Awards $9.9 Million Grant for the Development of HUMACYL®

May 13, 2016

Humacyte Commences Phase III Clinical Trial of Human Acellular Vessel

May 13, 2016

Humacyte’s Phase II Bioengineered Blood Vessel Study Results Published in The Lancet

April 25, 2016

Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association

November 9, 2015

Humacyte’s Chief Medical Officer and Vascular Surgeon, Dr. Jeffrey Lawson, to Address Upcoming VEITHsymposium

November 2, 2015

Humacyte Founder Laura Niklason, M.D., Ph.D. to Present at the American Heart Association Scientific Sessions

October 20, 2015

Humacyte Raises $150 Million Series B Financing

October 20, 2015

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Medicine

October 5, 2015

Humacyte Appoints Dr. Jeffrey H. Lawson as Chief Medical Officer

September 8, 2015

Humacyte Founder Dr. Laura Niklason and Board Director Dr. Robert Langer to address the 4th TERMIS World Congress in Boston

September 2, 2015

Humacyte Appoints the Honorable Kathleen Sebelius and Dale A. Sander to Board of Directors

May 28, 2015

Vascular Surgeon Dr. Jeffrey H. Lawson to Present on Tissue Engineering of Vascular Access Grafts at 2015 VASA Practicum

March 2, 2015

Humacyte Receives 2015 North Carolina Excellence Award

January 26, 2015

Surgeon, Dr. Jeffrey H. Lawson, to Present on Bioengineering and the Potential to Create New Blood Vessels at the International Symposium for Endovascular Therapy

October 20, 2014

Humacyte Selected to Join U.S. Secretary of Commerce On Trade Mission to Asia

July 23, 2014

Humacyte Receives Fast Track Designation for HumaGraft™ for Vascular Access in Hemodialysis Program

November 20, 2013

Humacyte Presents Interim First-In-Human Data For Investigational Bioengineered Blood Vessel At The American Heart Association (AHA) Scientific Sessions 2013

November 19, 2013

Investigational Bioengineered Vessels Update Is Presented at the 40th Annual VEITHsymposium in New York

October 31, 2013

Humacyte Receives 2013 North Carolina Excellence Award

October 11, 2013

AlloSource and Humacyte Become Strategic Manufacturing Partners to Create Investigational Bioengineered Blood Vessels from Tissue Donor Cells

June 6, 2013

Surgeons at Duke University Hospital Implant Bioengineered Vein

April 26, 2013

Humacyte Announces Clinical Milestones in its Novel Bioengineered Investigational Biologic Blood Vessel Technology

April 25, 2013

“Off-the-shelf” Investigational Biologic Artificial Blood Vessels May Reduce Dialysis Complications

October 3, 2011

Humacyte in Popular Mechanics

August 29, 2017

NHLBI publishes online article on Humacyte’s Next-generation replacement blood vessels target kidney and heart disease

May 30, 2017

Profiles in Diversity Journal Announces its 2017 Women Worth Watching Awards

May 22, 2017

New FDA Pathway to Accelerate Development of Cell Therapies

May 9, 2017

110 Women in Medtech to Know

December 1, 2016

Bioengineered Vessel Evaluated in Research Study

September 12, 2016

Overlook Medical Center First-in-State to Implant Human-Tissue Vessel as Part of Hemodialysis Access Clinical Trial

June 26, 2016

Six New Medical Technologies Worth Watching

June 8, 2016

Inside the sci-fi world of growing human tissue and organs in the lab

June 6, 2016

Humacyte, a bioengineered blood vessel

May 24, 2016

10 Women Who Would Be a Great Addition to Any Company’s Board

May 18, 2016

RTP’s Humacyte makes big steps with Lancet publication and Phase 3 Trial

May 13, 2016

Humacyte launches pivotal trial for lab-grown blood vessel

April 30, 2016

What Does It Take to Outperform the S&P 500? We Asked a Board Member Who Does It

Awards &
Acknowledgements

Humacyte Founder
Laura Niklason, M.D., Ph.D. Named
to the 2017 PharmaVoice100
List Awards Finalist

Dr. Niklason was recognized by PharmaVoice for her
contributions to the advancement of regenerative medicine,
in creating investigational human acellular vessels.

Humacyte Founder
Laura Niklason, M.D., Ph.D. Inducted
into the Women in Technology (WITI) Hall of Fame

Dr. Niklason was inducted into the Women in Technology
Fall of Fame for her groundbreaking research in regenerative
strategies for cardiovascular and lung tissues.

Humacyte’s Heather Prichard, Ph.D.,
named as a 2017 award winner for
Diversity Journal’s Women Worth
Watching in STEM

Senior Vice President, Product Development Dr. Heather
Prichard was named as a 2017 award winner for Diversity
Journal’s Women Worth Watching in STEM in recognition of
her work to develop technologies for improving medical
treatment for a variety of diseases.

Humacyte® Selected as 2017
Technology Pioneer by
World Economic Forum

Humacyte was selected as a 2017 Technology Pioneer by
the World Economic Forum for the potential to significantly
impact business and society through new technologies
in regenerative medicine.

Humacyte’s Juliana Blum and
Jenny Jackson Named to Profiles
in Diversity Journal’s 2017 Women Worth Watching List

Dr. Juliana Blum, Co-Founder and Vice-President, Business
Operations & Tissue Services and Jenny Jackson, Associate
Director of Reimbursement for Humacyte, were recognized to
Diversity Journal’s Women Worth Watching in 2017 award for
their personal and professional contributions to advancing
gender diversity.

Humacyte Founder
Dr. Laura Niklason and Humacyte
CEO Carrie Cox Named to
Becker’s Hospital Review List
of 110 Women in Medtech to Know

Humacyte Founder, Dr. Niklason and Humacyte CEO,
Carrie Cox were both recognized to Becker’s Hospital
Review, “110 Women in Medtech to Know”

Humacyte Founder
Laura Niklason, M.D., Ph.D.
Recognized on Fortune
Magazine’s List of Leaders
Transforming Health and Medicine

Dr. Niklason was recognized to Fortune Magazine’s prestigious
List of Leaders Transforming Health and Medicine, for her
contributions to the advancement of regenerative medicine,
in creating investigational human acellular vessels.

Humacyte Founder Dr.
Laura Niklason, M.D., Ph.D.
awarded with a 2016
LAS Alumni Achievement Award

Dr. Laura Niklason received a LAS Alumni Achievement
Award from the University of Illinois College of Liberal
Arts & Sciences for groundbreaking work in tissue
engineering in 2016.

Humacyte named 2016 Fierce
Innovation Awards finalist

Humacyte was named to Fierce Innovation’s Awards Life
Sciences Edition in 2016 for creating HUMACYL

Humacyte named to FierceBiotech’s
Top 15 Private Companies in the
Medical Devices Space for 2016

Humacyte was named to FierceBiotech’s Top 15 Private
Companies in Medical Devices for the potential to significantly
impact business and society through new technologies
in regenerative medicine.

WSJ Includes Humacyl
as one of “Six New Medical
Technologies Worth Watching”

Humacyte was highlighted as a potential breakthrough
for patients undergoing hemodialysis.

Humacyte makes CNBC
Disruptor 50 List

Humacyte was named to CNBC’s prestigious Disrupt 50
List for the progress HUMACYL has made since
Humacyte’s founding.

Humacyte Chief Medical Officer
Jeffrey H. Lawson M.D., Ph.D.
Elected to Fellowship in
the American Surgical Association

Humacyte’s Chief Medical Officer, Dr. Jeffery H. Lawson
was elected as a Fellow to the prominent American Surgical
Association for his experience and leadership as a
medical professional.

Humacyte Founder
Laura Niklason, M.D., Ph.D.
Elected to National Academy of Medicine

Laura Niklason, M.D., Ph.D., a world leader in tissue
engineering and cellular therapies and Founder of Humacyte,
has been elected to the prestigious National Academy of
Medicine (NAM). NAM is an independent organization of
eminent professionals from diverse fields including health
and medicine; the natural, social, and behavioral sciences,
and beyond.

North Carolina
Excellence Award

Humacyte, an innovator in biotechnology and regenerative
medicine, announced today that the Company has been awarded
the 2015 North Carolina Excellence Award by the US Commerce
& Trade Research Institute (USCTRI), a leading research
authority that evaluates and recognizes businesses and
organizations that have made a significant contribution
in enterprise and entrepreneurial growth.

Excellence in
Commerce Award

The Small Business Institute for Excellence in Commerce
(SBIEC) recognizes Humacyte with the 2013 North Carolina
Excellence Award for continued advancement of business
leadership and high regard for upholding business ethics
and company values among its peers.

Top 10 Women
in Biotech

Fierce Biotech names Carrie Cox as one of the
“Top 10 Women in Biotech”

Fast Company 
Top 50 World’s Most
Innovative Companies

Fast Company names Humacyte as one of the “Top 50
World’s Most Innovative Companies”

Popular Mechanics 
Breakthrough Innovation of 2011

Popular Mechanics recognizes Humacyte investigational
bioengineered blood vessel technology as a “Breakthrough
Innovation of 2011.” This technology is under clinical
study by Humacyte, and Humacyte plans to seek FDA
approval of the technology.

Frost & Sullivan
New Product Innovation

Humacyte receives Frost & Sullivan Award for New
Product Innovation

Coming to a city near you.

EVENT
DATE
LOCATION
EVENT TYPE
American College of Surgeons (ACS) – Clinical Congress 2018
October 21-25, 2018
Boston, MA
Attendee
2017 CNBC Net/Net Summit
October 25, 2017
New York, NY
Business & Networking
Women in Technology International 23rd Annual Women in Technology Summit
June 11-13, 2017
San Jose, California
Recognition & Panel Discussion
ASDIN (American Society of Diagnostic and Interventional Nephrology)
February 10-12, 2017
New Orleans, Louisiana
Presentation
2018 Renal Physicians Association (RPA)
March 15 – 18, 2018
Orlando, FL
Presentation
Charing Cross Symposium 2018
April 24-27, 2018
London, UK
Attendee
Sixth Annual Kidney Health Initiative (KHI) Stakeholders Meeting
May 14-15, 2018
Silver Springs, MD
Attendee
Show past events